Meme Kanseri Tedavisinde Nanopartikül Tabanlı İlaç Taşıma Sistemleri ve Hedefleme Stratejileri

Year 2025, Volume: 8 Issue: 1, 81 - 101, 30.04.2025

Ceren Çolak

https://doi.org/10.46373/hafebid.1652048

Abstract

Breast cancer continues to be a major contributor to cancer-related mortality globally,
highlighting the critical importance of developing more efficient and safer therapy
strategies. Nanoparticle-based drug delivery systems offer a promising approach by
enhancing drug accumulation in tumor tissues while minimizing systemic toxicity.
This article explores the unique properties and advantages of various nanoparticles,
including liposomal, polymer-, metal-, carbon- and mesoporous silica nanoparticles,
in breast cancer therapy. Additionally, it delves into three key targeting mechanisms:
passive targeting via the enhanced permeability and retention (EPR) effect, active
targeting using ligands and antibodies, and stimuli-responsive drug delivery systems.
Integrating nanotechnology into breast cancer therapy paves the way for more
precise, efficient, and personalized therapy options, offering new hope for improved
patient outcomes.
Keywords: Breast Cance

Keywords

Meme Kanseri, İlaç Dağıtım Sistemleri, Nanopartikül

Nanoparticle-Based Drug Delivery Systems and Targeting Strategies in Breast Cancer Therapy

Abstract

Breast cancer continues to be a major contributor to cancer-related mortality globally, highliting the critical importance of developing more efficient and safer therapy strategies. Nanoparticle-based drug delivery systems offer a promising approach by enhancing drug accumulation in tumor tissues while minimizing systemic toxicity. This article explores the unique properties and advantages of various nanoparticles, including liposomal, polymer-, carbon- and mesoporous silica nanoparticles, in breast cancer therapy. Additionally, it delves into three key targeting mechanisms: passive targeting via the enhanced permeability and retention (EPR) effect, active targeting using ligands and antibodies, and stimuli-responsive drug delivery systems. Integrating nanotechnology into breast cancer therapy paves the way for more precise, efficient, and personalized therapy options, offering new hope for improved patient outcomes.

Keywords

Breast Cancer, Drug Delivery Systems, Nanoparticle

References

• Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
• Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7–33. https://doi.org/10.3322/caac.21654
• DeSantis, C. E., et al. (2019). Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(6), 438–451. https://doi.org/10.3322/caac.21583
• Torre, L. A., Islami, F., Siegel, R. L., Ward, E. M., & Jemal, A. (2017). Global cancer in women: Burden and trends. Cancer Epidemiology, Biomarkers & Prevention, 26(4), 444–457. https://doi.org/10.1158/1055-9965.EPI-16-0858
• Lehmann, B. D., et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation, 121(7), 2750–2767. https://doi.org/10.1172/jci45014
• Sørlie, T., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences, 98(19), 10869–10874. https://doi.org/10.1073/pnas.191367098
• Slamon, D. J., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344(11), 783–792. https://doi.org/10.1056/nejm200103153441101
• Mavaddat, N., et al. (2019). Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. American Journal of Human Genetics, 104(1), 21–34. https://doi.org/10.1016/j.ajhg.2018.11.002
• Cardoso, F., et al. (2019). Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 30(8), 1194–1220. https://doi.org/10.1093/annonc/mdz173
• Stehr, M., Deilmann, K., Haas, R. J., & Dietz, H. G. (2005). Surgical complications in the treatment of Wilms’ tumor. European Journal of Pediatric Surgery, 15(6), 414–419. https://doi.org/10.1055/s-2005-872915
• Chaudhari, R., Patel, V., & Kumar, A. (2024). Cutting-edge approaches for targeted drug delivery in breast cancer: Beyond conventional therapies. Nanoscale. https://doi.org/10.1039/d4na00086b
• Darby, S., et al. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. The Lancet, 378(9804), 1707–1716. https://doi.org/10.1016/s0140-6736(11)61629-2
• Emens, L. A. (2018). Breast cancer immunotherapy: Facts and hopes. Clinical Cancer Research, 24(3), 511–520. https://doi.org/10.1158/1078-0432.ccr-16-3001
• Prat, A., et al. (2013). Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The Oncologist, 18(2), 123–133. https://doi.org/10.1634/theoncologist.2012-0397
• Manzari, M. T., et al. (2021). Targeted drug delivery strategies for precision medicines. Nature Reviews Materials, 6(4), 351–370. https://doi.org/10.1038/s41578-020-00269-6
• Rosenblum, D., et al. (2018). Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-03705-y
• Peer, D., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751–760. https://doi.org/10.1038/nnano.2007.387
• Fang, J., Nakamura, H., & Maeda, H. (2011). The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced Drug Delivery Reviews, 63(3), 136–151. https://doi.org/10.1016/j.addr.2010.04.009
• Torchilin, V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews, 63(3), 131–135. https://doi.org/10.1016/j.addr.2010.03.011
• Boman, N. L., et al. (1998). Liposomal vincristine: The central role of drug retention in defining therapeutically optimized anticancer formulations. In Long Circulating Liposomes: Old Drugs, New Therapeutics (pp. 29–49). https://doi.org/10.1007/978-3-662-22115-0_3
• Vahed, S. Z., et al. (2021). Mesoporous silica nanoparticles for smart delivery of therapeutics: A comprehensive review of safety, toxicity, and biodegradation. Journal of Controlled Release, 337, 1–27. https://doi.org/10.1016/j.jconrel.2021.07.016
• Mehnert, W., & Mäder, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews, 47(2–3), 165–196. https://doi.org/10.1016/s0169-409x(01)00105-3
• Shi, J., et al. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37. https://doi.org/10.1038/nrc.2016.108
• Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), 941–951. https://doi.org/10.1038/nbt.3330
• Bai, Y., et al. (2020). MOF-mediated delivery of nanosized paclitaxel to improve the antitumor effect in vivo. Journal of Materials Chemistry B, 8(15), 3250–3257. https://doi.org/10.1039/d0tb00363d
• Xu, X., et al. (2020). Co-delivery of paclitaxel and curcumin by PEGylated liposomes to improve anti-breast cancer treatment. International Journal of Nanomedicine, 15, 6349–6362. https://doi.org/10.2147/ijn.s253759
• Wang, Y., et al. (2020). Recent advances in the development of polymeric micelles for the treatment of breast cancer. Nanomedicine, 15(10), 941–957. https://doi.org/10.2217/nnm-2020-0029
• Zhao, Y., et al. (2020). Targeted co-delivery of doxorubicin and paclitaxel by folic acid-modified lipid-polymer hybrid nanoparticles for breast cancer treatment. International Journal of Nanomedicine, 15, 3583–3596. https://doi.org/10.2147/ijn.s241050
• Maeda, H., & Khatami, M. (2018). Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clinical and Translational Medicine, 7(1), 11. https://doi.org/10.1186/s40169-018-0185-6
• Jiang, Y., et al. (2019). Single-particle tracking reveals that binding kinetics of nanocarriers to the cell membrane modulates their transport behavior. Nature Nanotechnology, 14(9), 874–882. https://doi.org/10.1038/s41565-019-0490-y
• Li, S. Y., et al. (2016). Self-assembled cRGD–polyethylene glycol–paclitaxel micelles for targeted therapy of triple-negative breast cancer. Molecular Pharmaceutics, 13(9), 3152–3160. https://doi.org/10.1021/acs.molpharmaceut.6b00412